[1]
Simonneau G,Montani D,Celermajer DS,Denton CP,Gatzoulis MA,Krowka M,Williams PG,Souza R, Haemodynamic definitions and updated clinical classification of pulmonary hypertension. The European respiratory journal. 2019 Jan;
[PubMed PMID: 30545968]
[2]
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S, ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European heart journal. 2022 Oct 11:43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Epub
[PubMed PMID: 36017548]
[3]
Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC).,European Respiratory Society (ERS).,International Society of Heart and Lung Transplantation (ISHLT).,Galiè N,Hoeper MM,Humbert M,Torbicki A,Vachiery JL,Barbera JA,Beghetti M,Corris P,Gaine S,Gibbs JS,Gomez-Sanchez MA,Jondeau G,Klepetko W,Opitz C,Peacock A,Rubin L,Zellweger M,Simonneau G, Guidelines for the diagnosis and treatment of pulmonary hypertension. The European respiratory journal. 2009 Dec;
[PubMed PMID: 19749199]
[4]
Seeger W,Adir Y,Barberà JA,Champion H,Coghlan JG,Cottin V,De Marco T,Galiè N,Ghio S,Gibbs S,Martinez FJ,Semigran MJ,Simonneau G,Wells AU,Vachiéry JL, Pulmonary hypertension in chronic lung diseases. Journal of the American College of Cardiology. 2013 Dec 24;
[PubMed PMID: 24355635]
[5]
Nathan SD,Barbera JA,Gaine SP,Harari S,Martinez FJ,Olschewski H,Olsson KM,Peacock AJ,Pepke-Zaba J,Provencher S,Weissmann N,Seeger W, Pulmonary hypertension in chronic lung disease and hypoxia. The European respiratory journal. 2019 Jan;
[PubMed PMID: 30545980]
[6]
Varghese NP,Tillman RH,Keller RL, Pulmonary hypertension is an important co-morbidity in developmental lung diseases of infancy: Bronchopulmonary dysplasia and congenital diaphragmatic hernia. Pediatric pulmonology. 2021 Mar;
[PubMed PMID: 33561308]
[7]
Mirrakhimov AE,Strohl KP, High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management. The open cardiovascular medicine journal. 2016;
[PubMed PMID: 27014374]
[8]
Castro-Añón O,Golpe R,Pérez-de-Llano LA,López González MJ,Escalona Velasquez EJ,Pérez Fernández R,Testa Fernández A,González Quintela A, Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome. Respirology (Carlton, Vic.). 2012 Nov;
[PubMed PMID: 22897169]
[9]
Nagaoka M,Goda A,Takeuchi K,Kikuchi H,Finger M,Inami T,Soejima K,Satoh T, Nocturnal Hypoxemia, But Not Sleep Apnea, Is Associated With a Poor Prognosis in Patients With Pulmonary Arterial Hypertension. Circulation journal : official journal of the Japanese Circulation Society. 2018 Nov 24;
[PubMed PMID: 30333436]
[10]
Elwing J,Panos RJ, Pulmonary hypertension associated with COPD. International journal of chronic obstructive pulmonary disease. 2008;
[PubMed PMID: 18488429]
[11]
Zhang L,Liu Y,Zhao S,Wang Z,Zhang M,Zhang S,Wang X,Zhang S,Zhang W,Hao L,Jiao G, The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis. International journal of chronic obstructive pulmonary disease. 2022;
[PubMed PMID: 35711174]
Level 1 (high-level) evidence
[12]
Nathan SD,Shlobin OA,Ahmad S,Koch J,Barnett SD,Ad N,Burton N,Leslie K, Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration; international review of thoracic diseases. 2008;
[PubMed PMID: 18216461]
[13]
Lumb AB,Slinger P, Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology. 2015 Apr;
[PubMed PMID: 25587641]
[14]
Christou H,Khalil RA, Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies. American journal of physiology. Heart and circulatory physiology. 2022 May 1;
[PubMed PMID: 35213243]
[16]
Rahaghi FF,Kolaitis NA,Adegunsoye A,de Andrade JA,Flaherty KR,Lancaster LH,Lee JS,Levine DJ,Preston IR,Safdar Z,Saggar R,Sahay S,Scholand MB,Shlobin OA,Zisman DA,Nathan SD, Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study. Chest. 2022 Jul;
[PubMed PMID: 35176276]
[17]
Shellenberger RA,Imtiaz K,Chellappa N,Gundapanneni L,Scheidel C,Handa R,Bhat A, Physical Examination for the Detection of Pulmonary Hypertension: A Systematic Review. Cureus. 2021 Sep;
[PubMed PMID: 34692270]
Level 1 (high-level) evidence
[18]
Braganza M,Shaw J,Solverson K,Vis D,Janovcik J,Varughese RA,Thakrar MV,Hirani N,Helmersen D,Weatherald J, A Prospective Evaluation of the Diagnostic Accuracy of the Physical Examination for Pulmonary Hypertension. Chest. 2019 May;
[PubMed PMID: 30826305]
[19]
Rose L,Prins KW,Archer SL,Pritzker M,Weir EK,Misialek JR,Thenappan T, Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2019 Feb;
[PubMed PMID: 30391191]
[20]
Zisman DA,Karlamangla AS,Kawut SM,Shlobin OA,Saggar R,Ross DJ,Schwarz MI,Belperio JA,Ardehali A,Lynch JP 3rd,Nathan SD, Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2008 Mar;
[PubMed PMID: 18198245]
Level 1 (high-level) evidence
[21]
Lettieri CJ,Nathan SD,Barnett SD,Ahmad S,Shorr AF, Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006 Mar;
[PubMed PMID: 16537877]
[22]
Swigris JJ,Olson AL,Shlobin OA,Ahmad S,Brown KK,Nathan SD, Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.). 2011 Apr;
[PubMed PMID: 20946337]
[23]
Arcasoy SM,Christie JD,Ferrari VA,Sutton MS,Zisman DA,Blumenthal NP,Pochettino A,Kotloff RM, Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. American journal of respiratory and critical care medicine. 2003 Mar 1;
[PubMed PMID: 12480614]
[24]
Nowak J,Hudzik B,Jastrzȩbski D,Niedziela JT,Rozentryt P,Wojarski J,Ochman M,Karolak W,Żegleń S,Gierlotka M,Gąsior M, Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation. The clinical respiratory journal. 2018 Mar;
[PubMed PMID: 28052583]
[25]
Leuchte HH,Neurohr C,Baumgartner R,Holzapfel M,Giehrl W,Vogeser M,Behr J, Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. American journal of respiratory and critical care medicine. 2004 Aug 15;
[PubMed PMID: 15087298]
[26]
Song JW,Song JK,Kim DS, Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respiratory medicine. 2009 Feb;
[PubMed PMID: 19097877]
[27]
Zisman DA,Karlamangla AS,Ross DJ,Keane MP,Belperio JA,Saggar R,Lynch JP 3rd,Ardehali A,Goldin J, High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2007 Sep;
[PubMed PMID: 17573485]
[28]
Iyer AS,Wells JM,Vishin S,Bhatt SP,Wille KM,Dransfield MT, CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest. 2014 Apr;
[PubMed PMID: 24114440]
[29]
Yagi M,Taniguchi H,Kondoh Y,Ando M,Kimura T,Kataoka K,Furukawa T,Suzuki A,Johkoh T,Hasegawa Y, CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.). 2017 Oct;
[PubMed PMID: 28488784]
[31]
Schönhofer B,Barchfeld T,Wenzel M,Köhler D, Long term effects of non-invasive mechanical ventilation on pulmonary haemodynamics in patients with chronic respiratory failure. Thorax. 2001 Jul;
[PubMed PMID: 11413350]
[32]
Shujaat A,Minkin R,Eden E, Pulmonary hypertension and chronic cor pulmonale in COPD. International journal of chronic obstructive pulmonary disease. 2007;
[PubMed PMID: 18229565]
[33]
Weitzenblum E,Sautegeau A,Ehrhart M,Mammosser M,Pelletier A, Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. The American review of respiratory disease. 1985 Apr;
[PubMed PMID: 3922267]
[34]
Barberà JA,Peinado VI,Santos S, Pulmonary hypertension in chronic obstructive pulmonary disease. The European respiratory journal. 2003 May;
[PubMed PMID: 12765440]
[35]
Raghu G,Behr J,Brown KK,Egan JJ,Kawut SM,Flaherty KR,Martinez FJ,Nathan SD,Wells AU,Collard HR,Costabel U,Richeldi L,de Andrade J,Khalil N,Morrison LD,Lederer DJ,Shao L,Li X,Pedersen PS,Montgomery AB,Chien JW,O'Riordan TG,ARTEMIS-IPF Investigators*., Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Annals of internal medicine. 2013 May 7;
[PubMed PMID: 23648946]
Level 1 (high-level) evidence
[36]
Raghu G,Million-Rousseau R,Morganti A,Perchenet L,Behr J,MUSIC Study Group., Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. The European respiratory journal. 2013 Dec;
[PubMed PMID: 23682110]
Level 1 (high-level) evidence
[37]
Stolz D,Rasch H,Linka A,Di Valentino M,Meyer A,Brutsche M,Tamm M, A randomised, controlled trial of bosentan in severe COPD. The European respiratory journal. 2008 Sep;
[PubMed PMID: 18448495]
Level 1 (high-level) evidence
[38]
Nathan SD,Behr J,Collard HR,Cottin V,Hoeper MM,Martinez FJ,Corte TJ,Keogh AM,Leuchte H,Mogulkoc N,Ulrich S,Wuyts WA,Yao Z,Boateng F,Wells AU, Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. The Lancet. Respiratory medicine. 2019 Sep;
[PubMed PMID: 31416769]
Level 1 (high-level) evidence
[39]
Kang J,Song JW, Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Scientific reports. 2021 Sep 8;
[PubMed PMID: 34497295]
[40]
Goudie AR,Lipworth BJ,Hopkinson PJ,Wei L,Struthers AD, Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. The Lancet. Respiratory medicine. 2014 Apr;
[PubMed PMID: 24717626]
Level 1 (high-level) evidence
[41]
Waxman A,Restrepo-Jaramillo R,Thenappan T,Ravichandran A,Engel P,Bajwa A,Allen R,Feldman J,Argula R,Smith P,Rollins K,Deng C,Peterson L,Bell H,Tapson V,Nathan SD, Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. The New England journal of medicine. 2021 Jan 28;
[PubMed PMID: 33440084]
[42]
Leard LE,Holm AM,Valapour M,Glanville AR,Attawar S,Aversa M,Campos SV,Christon LM,Cypel M,Dellgren G,Hartwig MG,Kapnadak SG,Kolaitis NA,Kotloff RM,Patterson CM,Shlobin OA,Smith PJ,Solé A,Solomon M,Weill D,Wijsenbeek MS,Willemse BWM,Arcasoy SM,Ramos KJ, Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2021 Nov;
[PubMed PMID: 34419372]
Level 3 (low-level) evidence
[43]
Reed RM,Eberlein M,Girgis RE,Hashmi S,Iacono A,Jones S,Netzer G,Scharf S, Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. The American journal of medicine. 2012 Dec;
[PubMed PMID: 22959785]
[44]
Chaouat A,Naeije R,Weitzenblum E, Pulmonary hypertension in COPD. The European respiratory journal. 2008 Nov;
[PubMed PMID: 18978137]
[45]
Blanco I,Tura-Ceide O,Peinado VI,Barberà JA, Updated Perspectives on Pulmonary Hypertension in COPD. International journal of chronic obstructive pulmonary disease. 2020;
[PubMed PMID: 32606641]
Level 3 (low-level) evidence
[46]
Mejía M,Carrillo G,Rojas-Serrano J,Estrada A,Suárez T,Alonso D,Barrientos E,Gaxiola M,Navarro C,Selman M, Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009 Jul;
[PubMed PMID: 19225068]
[47]
Singh N,Dorfmüller P,Shlobin OA,Ventetuolo CE, Group 3 Pulmonary Hypertension: From Bench to Bedside. Circulation research. 2022 Apr 29;
[PubMed PMID: 35482836]
[48]
Galiè N,Humbert M,Vachiery JL,Gibbs S,Lang I,Torbicki A,Simonneau G,Peacock A,Vonk Noordegraaf A,Beghetti M,Ghofrani A,Gomez Sanchez MA,Hansmann G,Klepetko W,Lancellotti P,Matucci M,McDonagh T,Pierard LA,Trindade PT,Zompatori M,Hoeper M,ESC Scientific Document Group ., 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European heart journal. 2016 Jan 1;
[PubMed PMID: 26320113]